https://orcid.org/0000-0001-6019-129X
References
- Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117(1):158–162. doi:10.1016/j.jaci.2005.09.04716387600
- Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc. 2012;33(Suppl 1):S113–S141. doi:10.2500/aap.2012.33.360322981425
- Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369–377. doi:10.1159/00035140423652808
- Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–1289. doi:10.1016/j.jaci.2012.01.07722418065
- BéruBé K, Prytherch Z, Job C, Hughes T. Human primary bronchial lung cell constructs: the new respiratory models. Toxicology. 2010;278(3):311–318. doi:10.1016/j.tox.2010.04.00420403407
- Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Constantino HR. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm. 2007;335(1–2):138–146. doi:10.1016/j.ijpharm.2006.11.01317174048
- Gizurarson S. The effect of cilia and the mucociliary clearance on successful drug delivery. Biol Pharm Bull. 2015;38(4):497–506. doi:10.1248/bpb.b14-0039825739664
- Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012;74(1):125–133. doi:10.1111/j.1365-2125.2012.04222.x22356350
- Bousquet J, Meltzer EO, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726–1732. doi:10.1016/j.jaip.2018.01.03129425904
- Dymista (azelastine hydrochloride and fluticasone propionate spray, metered) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; 2018.